Fig. 2
Computed tomography images of one of our study patients with metastatic bronchoalveolar carcinoma which harbored exon 19 deletion treated with afatinib as 2nd TKI therapy after failure to gefitinib and chemotherapy. a. Baseline images showing diffuse ground glass opacities representing tumor infiltrates in lower lobes of both lungs. b. CT images at 3 months after afatinib showing significant reduction of tumor infiltrates. c. CT images at 6 months after afatinib showing further response and tumor shrinkage to afatinib
